Massachusetts Society of Clinical Oncologists - FDA approves pembrolizumab (Keytruda) for first-line treatment of MSI-H/dMMR colorectal cancer

"The voice for cancer physicians and their patients in Massachusetts."

Home
Resources
FDA Approvals
FDA approves pembrolizumab (Keytruda) for first-line treatment of MSI-H/dMMR colorectal cancer

FDA approves pembrolizumab (Keytruda) for first-line treatment of MSI-H/dMMR colorectal cancer

27 Jul 2020 9:47 AM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration approved pembrolizumab (KEYTRUDA, Merck & Co.) for the first-line treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer. Read full press release.

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org